Pathogenesis, diagnosis, and treatment of hepatic encephalopathy.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical and Experimental Hepatology

• Publication date

  2011-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0973-6883(11)60126-6PMID 25755319PMCID PMC3940085
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.

  2011cited by this paper
• Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis.

  2011cited by this paper
• Rifaximin in the treatment of hepatic encephalopathy

  2011cited by this paper
• Rifaximin Improves Psychometric Performance and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy (The RIME Trial)

  2011cited by this paper
• Effects of Branched-Chain Amino Acids Supplementation in Patients With Cirrhosis and a Previous Episode of Hepatic Encephalopathy: A Randomized Study

  2011cited by this paper
• Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement

  2011cited by this paper
• Evidence for oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy

  2010cited by this paper
• Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis

  2010cited by this paper
• Rifaximin for the treatment of hepatic encephalopathy

  2010cited by this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cited by this paper
• Changing face of hepatic encephalopathy: role of inflammation and oxidative stress.

  2010cited by this paper
• Three targets of branched-chain amino acid supplementation in the treatment of liver disease.

  2010cited by this paper
• A double‐blind, randomized, placebo‐controlled trial of intravenous l‐ornithine–l‐aspartate on postural control in patients with cirrhosis

  2010cited by this paper
• Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.

  2010cited by this paper
• Reversibility of hepatic encephalopathy after liver transplantation

  2010cited by this paper
• Mechanisms, diagnosis and management of hepatic encephalopathy

  2010cited by this paper
• Performance of the Hepatic Encephalopathy Scoring Algorithm in a Clinical Trial of Patients With Cirrhosis and Severe Hepatic Encephalopathy

  2009cited by this paper
• Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines

  2009cited by this paper
• Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation

  2009cited by this paper
• Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy

  2009influential reference
• Minimal hepatic encephalopathy is associated with motor vehicle crashes: The reality beyond the driving test

  2009cited by this paper
• Probiotic Yogurt for the Treatment of Minimal Hepatic Encephalopathy

  2008cited by this paper
• Minimal hepatic encephalopathy matters in daily life.

  2008cited by this paper
• Computerized psychometric testing in minimal encephalopathy and modulation by nitrogen challenge and liver transplant.

  2008cited by this paper
• A Pilot Study Utilizing Nitazoxanide for Hepatic Encephalopathy in Chronic Liver Failure: 392

  2008cited by this paper
• Inhibitory control test for the diagnosis of minimal hepatic encephalopathy.

  2008cited by this paper
• Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA)

  2008cited by this paper
• The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy.

  2008cited by this paper
• MR Imaging Findings in Hepatic Encephalopathy

  2008cited by this paper
• The demise of the pencil? New computer-assisted tests for minimal hepatic encephalopathy.

  2008cited by this paper
• Development of a clinical hepatic encephalopathy staging scale

  2007cited by this paper
• Assessment of low-grade hepatic encephalopathy: a critical analysis.

  2007cited by this paper
• Inhibitory Control Test Is a Simple Method to Diagnose Minimal Hepatic Encephalopathy and Predict Development of Overt Hepatic Encephalopathy

  2007cited by this paper
• Role of ammonia and inflammation in minimal hepatic encephalopathy

  2007cited by this paper
• Spatio-temporal decomposition of the electroencephalogram in patients with cirrhosis.

  2007cited by this paper
• Lactulose improves cognitive functions and health‐related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

  2007cited by this paper
• Inflammation and hepatic encephalopathy: Ibuprofen restores learning ability in rats with portacaval shunts

  2007cited by this paper
• Hepatic encephalopathy and nitrogen metabolism

  2006cited by this paper
• Definition and assessment of low-grade hepatic encephalopathy

  2006cited by this paper
• The EEG assessment of low-grade hepatic encephalopathy: comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis.

  2006cited by this paper
• Treatment of hepatic encephalopathy.

  2005cited by this paper
• Normal protein diet for episodic hepatic encephalopathy: results of a randomized study.

  2004cited by this paper
• Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

  2004cited by this paper
• Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis.

  2004cited by this paper
• Benzodiazepine receptor antagonists for hepatic encephalopathy.

  2004cited by this paper
• Infection and the progression of hepatic encephalopathy in acute liver failure.

  2003cited by this paper
• Correlation between ammonia levels and the severity of hepatic encephalopathy.

  2003cited by this paper
• Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

  2003cited by this paper
• Branched-chain amino acids for hepatic encephalopathy.

  2003cited by this paper
• Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998

  2002cited by this paper
• 1H Magnetic Resonance in the Study of Hepatic Encephalopathy in Humans

  2002cited by this paper
• Critical flicker frequency for quantification of low‐grade hepatic encephalopathy

  2002cited by this paper
• Neuropsychological characterization of hepatic encephalopathy.

  2001cited by this paper
• Treatment of hepatic encephalopathy.

  2001cited by this paper
• Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy.

  2001cited by this paper
• Regional cerebral blood flow autoregulation in patients with fulminant hepatic failure

  2000cited by this paper
• Subclinical hepatic encephalopathy impairs daily functioning

  1998cited by this paper
• Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.

  1998cited by this paper
• L-Ornithine-L-Aspartate in Experimental Portal-Systemic Encephalopathy: Therapeutic Efficacy and Mechanism of Action

  1998cited by this paper
• Therapeutic efficacy of L‐ornithine‐L‐aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo‐controlled, double‐blind study

  1997cited by this paper
• Pathways and mechanisms for cytokine signaling of the central nervous system.

  1997cited by this paper
• Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy.

  1995cited by this paper
• Lactitol in treatment of chronic hepatic encephalopathy

  1993cited by this paper
• Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross‐over comparison

  1993cited by this paper
• Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.

  1992cited by this paper
• Effect of ammonium ions on synaptic transmission in the mammalian central nervous system.

  1992cited by this paper
• Sodium benzoate in the treatment of acute hepatic encephalopathy: A double‐blind randomized trial

  1992cited by this paper
• Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.

  1991cited by this paper
• Cerebral Ammonia Metabolism in Patients with Severe Liver Disease and Minimal Hepatic Encephalopathy

  1991cited by this paper
• Branched-chain amino acids in hepatic encephalopathy.

  1990cited by this paper
• Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis.

  1989cited by this paper
• Prognostic Significance of EEG Triphasic Waves in Patients with Altered State of Consciousness

  1989cited by this paper
• New mode of action for lactulose.

  1988cited by this paper
• Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal‐systemic encephalopathy: A double‐blind, randomized clinical trial

  1987cited by this paper
• Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial.

  1984cited by this paper
• Bromocriptine-associated hyponatraemia in cirrhosis.

  1982cited by this paper
• Treatment of hepatic encephalopathy with metronidazole.

  1982cited by this paper
• Blood and Brain Ammonia Concentrations After Portacaval Anastomosis. Effects of Acute Ammonia Loading

  1980cited by this paper
• The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia.

  1979cited by this paper
• The Hepatic Coma Syndromes and Lactulose

  1979cited by this paper
• The hepatic coma syndromes and lactulose: By H. O. Conn and M. M. Lieberthal. 419 pp., $42.00. Williams and Wilkins Company, Baltimore, Maryland

  1979cited by this paper
• Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts.

  1977cited by this paper
• Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.

  1977cited by this paper
• The neurological disorder associated with liver disease.

  1953cited by this paper
• The neurological disorder associated with liver disease.

  1953cited by this paper
• Ueber die Bestimmung des Ammoniaks in thierischen Flüssigkeiten und Geweben

  1895cited by this paper
• Ueber den Ammoniakgehalt des Blutes und der Organe und die Harnstoffbildung bei den Säugethieren

  1895cited by this paper

• Revealing the protective potential of D-(-)-Quinic acid against thioacetamide-induced hepatic encephalopathy in rats

  2025cites this paper
• Electron thermalization in ammonia clusters induced by femtosecond laser fields

  2025cites this paper
• Brain magnetic resonance imaging findings in hyperammonemic hepatic encephalopathy: A case series and literature review.

  2025influential citation
• Assessment of microstructural abnormalities in gray and white matter of minimal hepatic encephalopathy patients using diffusion kurtosis imaging and their associations with neurocognitive dysfunction

  2025cites this paper
• Meta‐analysis of probiotics efficacy in the treatment of minimum hepatic encephalopathy

  2024cites this paper
• Preventing Readmissions for Hepatic Encephalopathy.

  2024cites this paper
• Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study

  2022cites this paper
• Topic: Nutrition and the Gut-Liver-Brain Axis

  2022cites this paper
• Role of extracellular vesicles in liver diseases and their therapeutic potential.

  2021cites this paper
• Alcohol and the Nervous System

  2021cites this paper
• Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy

  2021influential citation
• Thalamic Structural Connectivity Abnormalities in Minimal Hepatic Encephalopathy

  2021cites this paper
• Acute Acquired Metabolic Encephalopathy Based on Diffusion MRI

  2021influential citation
• Therapeutic plasma exchange in liver failure

  2021cites this paper
• Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives

  2021cites this paper
• Renal and Brain Failure Predict Mortality of Patients with Acute-On-Chronic Liver Failure Admitted to the Intensive Care Unit.

  2020cites this paper
• Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis.

  2020cites this paper
• Reduced Cortical Complexity in Cirrhotic Patients with Minimal Hepatic Encephalopathy

  2020cites this paper
• Disturbance of thalamic metabolism and its association with regional neural dysfunction and cognitive impairment in minimal hepatic encephalopathy.

  2020cites this paper
• Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy

  2019cites this paper
• RETRACTED ARTICLE: Amygdalin reduces lipopolysaccharide-induced chronic liver injury in rats by down-regulating PI3K/AKT, JAK2/STAT3 and NF-κB signalling pathways

  2019cites this paper
• [Multiple organ manifestations of liver failure in acute small bowel obstruction].

  2019cites this paper
• Endogenous Expression of ODN-Related Peptides in Astrocytes Contributes to Cell Protection Against Oxidative Stress: Astrocyte-Neuron Crosstalk Relevance for Neuronal Survival

  2018cites this paper
• Identification of modules of hepatic encephalopathy based on protein-protein network and gene expression data

  2018cites this paper
• Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator‐blinded, active‐controlled trial and a phase III, multicenter, open trial

  2018cites this paper
• Arachidonic Acid Metabolism Pathway Is Not Only Dominant in Metabolic Modulation but Associated With Phenotypic Variation After Acute Hypoxia Exposure

  2018cites this paper
• L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.

  2018cites this paper
• The Cerebellum of Patients with Steatohepatitis Shows Lymphocyte Infiltration, Microglial Activation and Loss of Purkinje and Granular Neurons

  2018cites this paper
• Multimodal MR imaging in hepatic encephalopathy: state of the art

  2018cites this paper
• History Taking and Physical Examination for the Patient with Liver Disease

  2017cites this paper
• Nutritional and systemic metabolic disorders.

  2017cites this paper
• Carnosine Reduces Oxidative Stress and Reverses Attenuation of Righting and Postural Reflexes in Rats with Thioacetamide-Induced Liver Failure

  2016cites this paper
• L-ornithine L-aspartate for people with cirrhosis and hepatic encephalopathy

  2016cites this paper
• Gray matter alterations in cirrhosis with and without hepatic encephalopathy: a meta-analysis of voxel-based morphometry studies

  2016cites this paper
• [Hepatic encephalopathy].

  2016cites this paper
• Acute-On-Chronic Liver Failure

  2016cites this paper
• Comparación de la administración de lactulosa y metronidazol vs lactulosa o metronidazol en el tratamiento de la encefalopatía hepática aguda

  2016cites this paper
• Research progress on hepatic encephalopathy: animal models and disease mechanisms

  2015cites this paper
• THE CLINICAL EFFECTS OF NITAZOXANIDE IN HEPATIC ENCEPHALOPATHY PATIENTS: A PILOT STUDY

  2015cites this paper
• Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.

  2015cites this paper
• Cortical signature of patients with HBV-related cirrhosis without overt hepatic encephalopathy: a morphometric analysis

  2015cites this paper
• Multimodality magnetic resonance imaging in hepatic encephalopathy: an update.

  2014cites this paper
• Hyperammonia induces specific liver injury through an intrinsic Ca2+-independent apoptosis pathway

  2014cites this paper
• Hepatobiliary quiz-10 (2014).

  2014cites this paper
• Extensive Cortical Diffusion Restriction in a 50-Year-Old Female with Hyperammonemic Encephalopathy and Status Epilepticus

  2014cites this paper
• Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.

  2014cites this paper
• Gut microbiota and hepatic encephalopathy

  2013cites this paper
• RECENT THEORIES OF PATHOGENESIS OF HEPATIC ENCEPHALOPATHY IN HEPATITIS C VIRAL INFECTION

  2013cites this paper
• RECENT THEORIES OF PATHOGENESIS OF HEPATIC ENCEPHALOPATHY IN HEPATITIS C VIRAL INFECTION

  2013cites this paper
• A study on the position and etiology of infection in cirrhotic patients: A potential precipitating factor contributing to hepatic encephalopathy

  2013cites this paper
• Role of the heme oxygenase/carbon monoxide pathway in the pathogenesis and prevention of hepatic encephalopathy.

  2013cites this paper
• Gut microbiota, inflammation and hepatic encephalopathy: a puzzle with a solution in sight.

  2012influential citation
• Answers to multiple choice questions.

  2012cites this paper
• Brain perfusion single photon emission computed tomography abnormalities in patients with minimal hepatic encephalopathy.

  2012cites this paper
• Answers to multiple choice questions.

  2012cites this paper
• Multiple choice questions.

  2012cites this paper
• World Journal of Hepatology

  year unknowncites this paper
• LIVER Probiotic VSL # 3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis : A Randomized , Controlled Trial

  year unknowncites this paper